Navidea Biopharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAVB research report →
About the company
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to creating and marketing highly specific diagnostic tools that leverage the immune system, as well as therapeutic agents also based on immune principles. Its operations are divided into two primary divisions: Diagnostic Substances and Therapeutic Development Programs.
- CEO
- Craig A. Dais CPA
- IPO
- 1992
- Employees
- 11
- HQ
- Dublin, OH, US
Price Chart
- Market Cap
- $10.01K
- P/E
- -0.00
- P/S
- 0.15
- P/B
- -0.00
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
- Gross Margin
- -259.40%
- Op Margin
- -21402.08%
- Net Margin
- -23117.58%
- ROE
- 355.34%
- ROIC
- 280.59%
- Revenue
- $65.65K · -87.65%
- Net Income
- $-15,177,153 · -29.38%
- EPS
- $-0.59 · -47.50%
- Op Income
- $-14,050,895
- FCF YoY
- 11.10%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.80
- Avg Volume
- 11.46K
Get TickerSpark's AI analysis on NAVB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 27, 21 | Rosol Michael Stanley | other | 100,000 |
Our NAVB coverage
Recent articles, reports, and earnings notes.
No research on NAVB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NAVB report →Similar companies
Peers in the same neighborhood.